DAFTAR PUSTAKA

Abdullah AA, Bujang N, Badril C, *et al*. 2009, 'The sensitivity and spesificity of a new scoring system using high resolution computed tomography to diagnose lung cancer', *Medical Journal of Indonesia*, vol. 18, pp. 179-86.

Agustina T dan Wulandari L, 2016, 'Perbandingan Respons Terapi Gefitinib Pada Pasien KPKBSK Dengan EGFR Mutasi Exon 19 dan Exon 21', Surabaya, Universitas Airlangga.

Ahmad Z, Raza P, Patel MR, 2015, 'Endometrial Metastasis of Lung Adenocarcinoma: A Report of Two Cases', *American Journal of Case Reports*, vol. 16, pp. 296-299.

American Cancer Society, 2017, 'Non-Small Cell Lung Cancer Survival Rates, by Stage', Available at : https://www.cancer.org/cancer/non-small-cell-lung-cancer/detection-diagnosis-staging/survival-rates.html [Accessed 11 April 2018].

Bartsch H, Nair U, Risch A, *et al.* 2000, 'Genetic Polymorphism of CYP Genes, Alone or in Combination, as a Risk Modifier of Tobacco-related Cancers', *Cancer Epidemiology, Biomarkers & Prevention*, vol. 9, pp. 3-28.

Batson OV, 1940, 'The function of vertebral veins and their role in spread of metastases', *Ann Surg*, vol. 112, pp. 138–149.

Boch C, Kollemeier J, Roth A, *et al*. 2013, 'The Frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from cohort study', *BMJ Open*, vol. 3, no. 4.

Brambilla E dan Gazdar A, 2009, 'Pathogenesis of lung cancer signalling pathways: roadmap for therapies', *European Respiratory Journal*, vol. 33, no. 6, pp. 1485-149.

Breindel JL, Haskins JW, Cowell EP, *et al.* 2013, 'EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis', *Cancer Res*, vol. 73, no. 16, pp. 5053–5065.

Dela Cruz CS, Tanoue LT, Matthay RA, 2013, 'Lung Cancer: Epidemiology, Etiology, and Prevention', *Clinical Chest Med*, vol. 32, no. 4.

Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT, 2017, 'The Eighth Edition Lung Cancer Stage Classification', *Chest*, vol. 151, no. 1, pp. 193-203.

Fatmawati F dan Wulandari L, 2016, 'Profil Pasien Kanker Paru Jenis Karsinoma Bukan Sel Kecil Yang Mendapatkan Inhibitor Tirosin Kinase Sebagai Terapi Lini Pertama Di RSUD Dr. Soetomo', Surabaya, Universitas Airlangga.

Fernández-Somoano A, Álvarez-Avellón SM, Souto-García A, *et al*. 2017, 'Alcohol Consumption and Lung Cancer According to Ile349Val Polymorphism in ADH3 Gene: Beyond the Tobacco Smoking Effect', *J Cancer 2017*, vol. 8, no. 12, pp. 2296-2302.

Gao SP, Mark KG, Leslie K, *et al*. 2007, 'Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinoma', *J Clin Invest*, vol. 117, no. 12, pp. 3846-3856.

Globocan, 2018, 'Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in 2012', Available at: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx [Accessed 12 April 2018]

Han B, Zhou X, Zhang RX, *et al*. 2011, 'Mutations of the epidermal growth factor receptor gene in NSCLC patients', *Oncology Letters*, vol. 2, pp. 1233-1237.

He Q, Zhang M, Zhang J, *et al*. 2015, 'Correlation between epidermal growth factor receptor mutations and nuclear expression of female hormone receptors in non-small cell lung cancer: a meta-analysis', *J Thorac Dis*, vol. 7, no. 9, pp. 1588-1594.

Husain A, Kumar V, 2005, 'The lung', *Robbins, Cotran. Pathologic Basis of Disease, 7th edition*, pp. 711-772, Philadelphia: Saunders

Kobayashi S, Boggon TJ, Dayaram T, *et al*. 2005, 'EGFR mutation and resistance of non-small-cell lung cancer to gefitinib', *N Engl J Med*, vol. 352, no. 8, pp. 786-792.

IASLC, 2017, 'IALSC Atlas of EGFR Testing in Lung Cancer', Editorial Rx Press, North Fort Myers, FL, U.S.A.

IASLC, 2018, 'Lung Cancer Fact and Statistic', Available at : http://wclc2017.iaslc.org/wp-content/uploads/2017/09/2017-WCLC-Fact-Sheet-Lung-Cancer-Final.pdf [Accessed 11 April 2018].

Indonesia Journal Chest, 2016, 'Kanker Paru: Sebuah Kajian Singkat', *Ina J Chest Crit and Emerg Med*, vol. 4, no. 1.

Kanwal M, Ding, XJ, Cao Y, 2017, 'Familial risk for lung cancer (Review)', *Oncology Letters*, vol. 13, no. 2, pp. 535-542.

Kemenkes RI, 2015, 'Stop Kanker', *Pusat Data dan Informasi Kementrian RI*, Available at: http://www.depkes.go.id/resources/download/pusdatin/infodatin/infodatin-kanker.pdf [Accessed 23 May 2018].

Kemenkes RI, 2017, 'Pedoman Nasional Pelayanan Kedokteran', Available at: http://kanker.kemkes.go.id/guidelines/PNPKParu.pdf [Accessed 12 April 2018].

Kosaka T, Yatabe Y, Endoh H, *et al*. 2004, 'Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications', *Cancer Res*, vol. 64, no. 24, pp. 8919-8923.

Krawczyk P, Nicoś M, Ramlau R, *et al*. 2014, 'The Incidence of EGFR-Activating Mutations in Bone Metastases of Lung Adenocarcinoma', *Pathology and Oncology Research*, vol. 20, no. 1, pp. 107-112.

Latimer KM dan Mott TF, 2015, 'Diagnosis, Treatment Principles, and Screening', *American Family Physician*, vol. 91, no. 4.

Lee SM, 2006, 'Is EGFR expression important in non-small cell lung cancer?', *Thorax*, vol. 61, no. 2, pp. 98-99.

Li AR, Chitale D, Riely G, *et al*. 2008, 'Clincal Testing Experience and Relationship to EGFR *Gene Copy Number and Immunohistochemical Expression', Journal of Molecular Diagnostics*, vol. 10, no. 3.

Li C, Sun Y, Fang Z, *et al*. 2011, 'Comprehensive Analysis of Epidermal Growth Factor Receptor Gene Status in Lung Adenocarcinoma', *Journal of Thoracic Oncology*, vol.6, no.6, pp. 1016-1021.

Li L, Luo S, Lin H, *et al*. 2017, 'Correlation between EGFR mutation status and the incidence of brain metastases in patients with non-small cell lung cancer', *Journal of Thoracic Diseases*, vol. 9, no. 8, pp. 2510-2520

Lin JJ, Cardarella S, Lydon CA, *et al*. 2015, 'Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs', vol. 11, no. 4, pp. 556-565.

Lindeman NI, Cagle PT, Beasley MB, *et al*. 2013, 'Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology', *J Thorac Oncol*, vol. 8, no. 7, pp. 823-859.

Mäkinen J, 2017, 'Lung Adenocarcinoma Histopathological Features And Their Association With Patient Outcome', Finlandia, *Universitatis Ouluensis*.

Márquez-Garbán DC, Chen HW, Fishbein MC, *et al*. 2007, 'Estrogen receptor signaling pathways in human non-small cell lung cancer', *Steroids*, vol. 72, no. 2, pp. 135-143.

Matsumoto S, Takahasi K, Iwakawa R, *et al*. 2006, 'Frequent EGFR mutations in brain metastases of lung adenocarcinoma', *Int J Cancer*, vol. 119, no. 6, pp. 1491–1494.

Midha A, Dearden S, McCormack R, 2015, 'EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)', *Am J Cancer* Res, vol. 5, no. 9, pp. 2892-2911.

NCCN, 2017, 'NCCN Clinical Practical Guidelines in Oncology Small Lung Cancer', Available at: https://www.tri-kobe.org/nccn/guideline/lung/english/small.pdf [Accessed 11 April 2018].

Nie Y, Gao W, Li N, Chen W, *et al*. 2017, 'Relationship between EGFR gene mutation and local metastasis of resectable lung adenocarcinoma', *World Journal of Surgical Oncology*, vol. 15, no. 55.

Noguchi M dan Shimosato Y, 'Pulmonary neoplasms', *Sternberg's Diagnostic Surgical Pathology, 5th edition*, pp. 1054–1095, Philadelphia: Lippincott Williams and Wilkins.

Nose N, Sugio K, Oyama T, *et al*. 2009, 'Association Between Estrogen Receptor-β Expression and Epidermal Growth Factor Receptor Mutation in the Postoperative Prognosis of Adenocarcinoma of the Lung', *Journal of Clinical Oncology*, vol. 27, no. 3.

Popper HH, 2016, 'Progression and metastasis of lung cancer', *Cancer Metastasis Rev*, vol. 35, pp. 75-91.

Purbonegoro T, Heriyanto DS, Anwar LS, 2016, 'Hubungan Usia dengan Mutasi Gen Epidermal Growth Factor Receptor Ekson 21 pada Pasien Dengan Kanker Paru Jenis Adenokarsinoma' Yogyakarta, Universitas Gajah Mada.

Occupational Safety and Health Administration, 2014, 'Asbestos', Available at: https://www.osha.gov/Publications/OSHA3507.pdf [Accessed 13April 2018].

Raja T dan Warrier NK, 2017, 'Epidermal growth factor receptor mutation testing: From conventional to real-time diagnosis of lung cancer', *Indian J Cancer*, vol. 54, pp. 9-14.

Riihimäki M, Hemminki A, Fallah M, *et al*. 2014, 'Metastatic Sites and Survival in Lung Cancer', *Lung Cancer*, vol. 86, no. 1, pp. 78-84.

Sadhegi-Gandomani H, Asgari-Tarazoj A, Ghoncheh M, *et al*. 2017, 'Lung Cancer In The World: The Incidence, Mortality Rate And Risk Factors', *World Cancer Research Journal*, vol. 4, no. 3.

Sari L dan Purwanto, 2016, 'Mutasi EGFR pada *Non-Small Cell Lung Cancer* di RS di Rumah Sakit Kanker Dharmais', *Indonesian Journal of Cancer*, vol. 10, no. 4.

Shi Y, Au JS, Thongprasert S, *et al*. 2014, 'A Prospective, Molecular Epidemiology Study of *EGFR* Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)', *Journal of Thoracic Oncology*, vol. 9 no. 2, pp. 154-162.

Shim HS, Chung JH, Kim L, *et al*. 2013, 'Guideline Recommendations for EGFR Mutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study Group', *The Korean Journal of Pathology*, vol. 47, no. 2, pp. 100-106.

Shigematsu H, Lin L, Takahashi K, *et al*. 2005, 'Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers', *Journal of the National Cancer Institute*, vol. 97, no. 5, pp. 339-346.

Sholl LM, 2015, 'Biomarkers in Lung Adenocarcinoma A Decade of Progress', *Arch Pathol Lab Med*, vol. 139, no. 4, pp. 469-480.

Singh M, Garg N, Venugopal C, *et al*. 2015, 'STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activation', *Oncotarget*, vol. 6, no. 29, pp. 27461-274677.

Sonobe M, Manabe T, Wada H, Tanaka F, 2005, 'Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma', *Br J Cancer*, vol. 8, no. 93, pp. 355-363.

Stabile LP, Lyker JS, Gubish CT, *et al*. 2005, 'Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects', *Cancer Res*, vol. 65, no. 4, pp. 1459-1470.

Sugiura H, Yamada K, Sugiura T, *et al*. 2008, 'Predictors of Survival in Patients with Bone Metastasis of Lung Cancer', *Clin Orthop Relat Res*, vol. 466, no. 3, pp.729-736.

Świątkowska, B, 2007, 'Modifiable risk factors for the prevention of lung cancer', *Rep Pract Oncol Radiother*, vol. 12, no. 2, pp. 119-124.

Travis WD, 2011, 'International Association for The Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma', *J Thorac Oncol*, vol. 6, no. 2, pp. 244–285.

Travis, WD, 2011, 'Pathology of Lung Cancer', Available at: https://pdfs.semanticscholar.org/1fae/6d662e32d104f920f9a6be9ffe6ba60a95a8.pdf [Accesed 15 April 2018].

Travis WD, 2015a, 'WHO Classification of Tumours of The Lung, Pleura, Thymus and Heart'. Lyon, IARC.

Togashi Y, Masago K, Kubo T, *et al*. 2011, 'Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma', *Cancer*, vol. 117, no. 4, pp. 819–825.

Vaezi A dan Grandis JR, 2014, 'Bailey's Head and Neck Surgery Otolaryngology fifth edition' *Head and Neck Tumor* Biology, Lippincott Williams&. Wilkins, a Wolters Kluwer business, pp. 1645-1670.

Wee P dan Wang Z, 2017, 'Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways', *Cancers*, vol. 9, no. 52.

WHO, 2014, 'Cancer Country Profile'. Available at : http://www.who.int/cancer/country-profiles/idn_en.pdf [Accessed 10 April 2018].

WHO, 2018, 'Fact Sheet' Available at : http://www.who.int/mediacentre/factsheets/fs297/en/ [Accessed 10 April 2018].

Wu CT, Chang YL, Shih JY, *et al*. 2005, 'The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers', *J Thorac Cardiovasc Surg*, vol. 130, no. 4, pp. 979-986.

Yasuda, H. *et al*, 2013, 'Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer', *Sci. Transl. Med*. vol. 5, no. 216.

Youlden DR, Cramb SM, Baade PD, 2008, 'The International Epidemiology of Lung Cancer Geographical Distribution and Secular Trends', *Journal of Thoracic Oncology*, vol. 3, no. 8, pp. 819-831.